Literature DB >> 20493424

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD).

Tim Zimmermann1, Maria Hoppe-Lotichius, Vuk Tripkovic, Ana P Barreiros, Thomas C Wehler, Anca Zimmermann, Jörn M Schattenberg, Michael Heise, Stefan Biesterfeld, Peter R Galle, Gerd Otto, Marcus Schuchmann.   

Abstract

BACKGROUND: Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.
METHODS: We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.
RESULTS: PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p<0.001). Moreover PTLD in immunocompromised patients with preoperative steroid treatment occurred at a significantly younger age (49.5+/-4.7 years) compared to patients without steroids (60.6+/-5.1 years; p=0.006). Multivariate analysis revealed pretransplant steroid treatment and liver transplantation for autoimmune hepatitis as main risk factors for the development of PTLD after liver transplantation (p<0.001).
CONCLUSION: Liver transplanted patients who received steroids before LT due to immunological disorders and patients with autoimmune hepatitis seem to be at particular high risk to develop PTLD. Prospective cohort studies including immunoepidemiologic investigations of abnormalities of cellular, humoral and innate immunity should be carried out to identify predictive factors and patients at risk. Copyright 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493424     DOI: 10.1016/j.ejim.2010.02.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.

Authors:  Khalid Mumtaz; Nabiha Faisal; Max Marquez; Alicia Healey; Leslie B Lilly; Eberhard L Renner
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-15

Review 2.  Posttransplant lymphoproliferative disease following liver transplantation.

Authors:  Kala Y Kamdar; Cliona M Rooney; Helen E Heslop
Journal:  Curr Opin Organ Transplant       Date:  2011-06       Impact factor: 2.640

3.  Posttransplant lymphoproliferative disease in liver transplant patients.

Authors:  Christina Hartmann; Marcus Schuchmann; Tim Zimmermann
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 4.  Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

Authors:  Daan Dierickx; Nina Cardinaels
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 5.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

Review 6.  Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.

Authors:  R Karbasi-Afshar; S Taheri
Journal:  Iran J Ped Hematol Oncol       Date:  2013-07-22

7.  Persistent indolent pancolonic marginal zone lymphoma of MALT-type with plasmacytic differentiation - A rare post-transplant lymphoma?

Authors:  Joanna M Chaffin; Natasha M Savage; Suash Sharma; Locke J Bryan; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol (N Y)       Date:  2017-07-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.